IAP inhibitor, Embelin increases VCAM-1 levels on the endothelium, producing lymphocytic infiltration and antitumor immunity

References

• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–11.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Nangia-Makker P, Hogan V, Raz A. Cancer self-defense: an immune stealth. Cancer Res. 2017;77:5441–5444. doi:10.1158/0008-5472.CAN-17-1324.
   PubMed Web of Science ®Google Scholar
• Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19:215–227.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156:2056–2072. doi:10.1053/j.gastro.2018.12.038.
   PubMed Web of Science ®Google Scholar
• Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381:244–251. doi:10.1016/j.canlet.2015.12.020.
   PubMed Web of Science ®Google Scholar
• Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan H-X. Immunotherapy for pancreatic cancer: A long and hopeful journey. Cancer Lett. 2018;425:143–151. doi:10.1016/j.canlet.2018.03.040.
   PubMed Web of Science ®Google Scholar
• Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923. doi:10.1038/bjc.2013.32.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 1782-90;2015:112.
   Google Scholar
• Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28–36. doi:10.1038/nm1699.
   PubMed Web of Science ®Google Scholar
• Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, Hubscher SG, Salmi M, Jalkanen S, Lalor PF, et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol. 2011;186(7):4147–4155. doi:10.4049/jimmunol.1002961.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–615. doi:10.1038/nm.3541.
   PubMed Web of Science ®Google Scholar
• Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. Hoboken (NJ): Wiley-Blackwell; 2017.
   Google Scholar
• Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology. 2011;140:310–321. doi:10.1053/j.gastro.2010.10.009.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450. doi:10.1016/S1535-6108(03)00309-X.
   PubMed Web of Science ®Google Scholar
• Friedl P, Weigelin B. Interstitial leukocyte migration and immune function. Nat Immunol. 2008;9:960–969.
   PubMed Web of Science ®Google Scholar
• Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182–1190. doi:10.1038/ni1275.
   PubMed Web of Science ®Google Scholar
• Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60–66. doi:10.1126/science.272.5258.60.
   PubMed Web of Science ®Google Scholar
• Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol. 2010;15:544–551.
   PubMed Web of Science ®Google Scholar
• Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–815.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–756.
   PubMed Web of Science ®Google Scholar
• Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261–270. doi:10.1038/nrm1357.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 2009;55:423–430. doi:10.1016/j.neuint.2009.04.011.
   PubMed Web of Science ®Google Scholar
• Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z. Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol. 2011;28:1584–1588. doi:10.1007/s12032-010-9601-5.
   PubMed Web of Science ®Google Scholar
• Peng M, Huang B, Zhang Q, Fu S, Wang D, Cheng X, Wu X, Xue Z, Zhang L, Zhang D, et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett. 2014;354:407–416. doi:10.1016/j.canlet.2014.08.011.
   PubMed Web of Science ®Google Scholar
• Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014;41:694–707. doi:10.1016/j.immuni.2014.10.008.
   PubMed Web of Science ®Google Scholar
• Blogowski W, Deskur A, Budkowska M, Salata D, Madej-Michniewicz A, Dabkowski K, Dołęgowska B, Starzyńska T. Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS One. 2014;9:e97613. doi:10.1371/journal.pone.0097613.
   PubMed Web of Science ®Google Scholar
• Lalaoui NV. D. L. Recent advances in understanding inhibitor of apoptosis proteins. F1000 Faculty Rev. 2019;7:1889.
   Google Scholar
• Bauler LD, Duckett CS, O’Riordan MX. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 2008;4:e1000142.
   PubMed Web of Science ®Google Scholar
• Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol. 2015;39:115–123. doi:10.1016/j.semcdb.2015.01.015.
   PubMed Web of Science ®Google Scholar
• Santoro MM, Samuel T, Mitchell T, Reed JC, Stainier DY. Birc2 (cIap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet. 2007;39:1397–1402. doi:10.1038/ng.2007.8.
   PubMed Web of Science ®Google Scholar
• Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 2008;105:11778–11783. doi:10.1073/pnas.0711122105.
   PubMed Web of Science ®Google Scholar
• Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem. 2000;275:22064–22068.
   PubMed Web of Science ®Google Scholar
• Kim J, Ahn S, Ko YG, Boo YC, Chi SG, Ni CW, Go YM, Jo H, Park H. X-linked inhibitor of apoptosis protein controls alpha5-integrin-mediated cell adhesion and migration. Am J Physiol Heart Circ Physiol. 2010;299:H300–9. doi:10.1152/ajpheart.00180.2010.
   PubMed Web of Science ®Google Scholar
• Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol. 2014;32(2):182–190. doi:10.1038/nbt.2806.
   PubMed Web of Science ®Google Scholar
• Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2016;8:339ra69.
   PubMed Web of Science ®Google Scholar
• Lalaoui N, Hanggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies L, Heckmann D, Ma C, Ghisi M, et al. Targeting p38 or MK2 enhances the anti-leukemic activity of smac-mimetics. Cancer Cell. 2016;29(2):145–158. doi:10.1016/j.ccell.2016.01.006.
   PubMed Web of Science ®Google Scholar
• Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016;22(12):1411–1420. doi:10.1038/nm.4229.
   PubMed Web of Science ®Google Scholar
• Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dranoff G, Dougan SK. IAP antagonists enhance cytokine production from mouse and human iNKT cells. Cancer Immunol Res. 2018;6:25–35.
   PubMed Web of Science ®Google Scholar
• Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010;207(10):2195–2206. doi:10.1084/jem.20101123.
   PubMed Web of Science ®Google Scholar
• Kim DS, Dastidar H, Zhang C, Zemp FJ, Lau K, Ernst M, Rakic A, Sikdar S, Rajwani J, Naumenko V, et al. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nat Commun. 2017;8:344. doi:10.1038/s41467-017-00324-x.
   PubMed Web of Science ®Google Scholar
• Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. Oncoimmunology. 2018;7:e1471440. doi:10.1080/2162402X.2018.1471440.
   PubMed Web of Science ®Google Scholar